Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Tryptamine Therapeutics ( (AU:TYP)) has ...
Hosted on MSN
ASX-listed Tryptamine Therapeutics launches binge eating trial using IV 'magic mushroom' drug
In a matter of weeks, Tryptamine Therapeutics (ASX:TYP) will become the world’s first company to conduct a study using IV-injected ‘magic mushroom’ psychedelic psilocin in a bid to manage binge eating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results